Xspray Pharma publishes its Annual Report 2023

Regulatory press release 2024-03-27

Xspray Pharma AB (publ) today publishes its Annual Report for the financial year 2023. The Annual Report is attached to this press release and available on the company’s website: https://xspraypharma.com/investors/financial-reports/

An extract from the CEO-letter from Per Andersson, CEO of Xspray Pharma:
“Throughout 2023, we continued to make significant progress on the exciting journey toward the launch of our product Dasynoc®. The settlement with Bristol Myers Squibb (BMS) in the patent dispute over Dasynoc® was a crucial milestone for the company, paving the way for the launch of our product in the beginning of September 2024 pending final FDA approval. We are working diligently to ensure a successful market launch of Dasynoc®.”